Advertisement
Canada markets closed
  • S&P/TSX

    22,673.52
    +129.39 (+0.57%)
     
  • S&P 500

    5,615.35
    +30.81 (+0.55%)
     
  • DOW

    40,000.90
    +247.15 (+0.62%)
     
  • CAD/USD

    0.7338
    +0.0001 (+0.02%)
     
  • CRUDE OIL

    82.18
    -0.44 (-0.53%)
     
  • Bitcoin CAD

    78,902.93
    +463.09 (+0.59%)
     
  • CMC Crypto 200

    1,212.03
    +13.46 (+1.12%)
     
  • GOLD FUTURES

    2,416.00
    -5.90 (-0.24%)
     
  • RUSSELL 2000

    2,148.27
    +23.23 (+1.09%)
     
  • 10-Yr Bond

    4.1890
    -0.0040 (-0.10%)
     
  • NASDAQ

    18,398.45
    +115.04 (+0.63%)
     
  • VOLATILITY

    12.46
    -0.46 (-3.56%)
     
  • FTSE

    8,252.91
    +29.57 (+0.36%)
     
  • NIKKEI 225

    41,190.68
    -1,033.34 (-2.45%)
     
  • CAD/EUR

    0.6722
    -0.0025 (-0.37%)
     

Sarepta Stock Surges on Expanded Elevidys Approval. It’s a ‘Best-Case’ Scenario for Shares.

Sarepta Stock Surges on Expanded Elevidys Approval. It’s a ‘Best-Case’ Scenario for Shares.

The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.